Silence Therapeutics plc

Regulatory Filings • Oct 30, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0694E

Silence Therapeutics PLC

30 October 2015

Silence Therapeutics plc

("Silence" or "the Company")

Licensee's drug to commence Phase 2 and Phase 3 trials

Further validation of our proprietary technology

The Company is aware of certain information released yesterday by SBI Holdings Inc., the parent of Quark Pharmaceuticals, Inc. ("Quark"), a wholly owned subsidiary of SBI Biotech Co., Ltd, which indicates that Quark is to begin, in December 2015, a Phase 3 trial in renal delayed graft function using its QPI-1002 drug. Quark will also begin a Phase 2 trial at the same time using QPI-1002 for acute kidney injury. Novartis has an option to license the drug in both indications.  Silence may receive potential milestone payments but has no future obligations in regard to these programmes. This is further validation of our proprietary technology which underpins Silence's own pipeline.

Enquiries:

Silence Therapeutics plc Ali Mortazavi, Chief Executive Officer Timothy Freeborn, Chief Financial Officer	Tel:  +44 (0)20 3457 6900
Canaccord Genuity Limited (Nominated Adviser and Joint Broker) Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel	Tel:  +44 (0)20 7523 8350
Peel Hunt LLP (Joint Broker) James Steel/Dr Tom Burt/Oliver Jackson	Tel:  +44 (0)20 7418 8900
Media Enquiries: FTI Consulting Simon Conway/Brett Pollard/Stephanie Cuthbert	Tel: +44 (0) 20 3727 1000

Notes to Editors

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells.  This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFVSIILIVIE